Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Blood and urine tests might be able to reveal how much of your diet is made up of industrially produced foods, a new study ...

Ltd. is advancing its commitment to sustainable weight management among Thais through the launch of the 'From My Weight to My Heart' campaign, aimed at reducing the risk of cardiovascular diseases and ...

About a fourth of younger men surveyed in the United States feel lonely, which is significantly higher than the national ...

Queen Latifah exclusively told Us Weekly about 'The Equalizer' coming to an end — and whether there is hope for a return ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Domestic pharmaceutical companies are stepping up in the insulin space. Lupin acquired Lilly’s Huminsulin brand, while Cipla ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...